Real-life efficacy and safety of nintedanib in systemic sclerosis-interstitial lung disease: data from an Italian multicentre study.

Campochiaro Corrado Giacomo DE LucaMaria-Grazia LazzaroniGiuseppe ArmentaroAmelia SpinellaBarbara VigoneBarbara RuaroAnna StanziolaDevis BenfaremoEnrico De LorenzisBeatrice MoccaldiSilvia Laura BoselloGiovanna CuomoLorenzo BerettaElisabetta ZanattaDilia GiuggioliNicoletta Del PapaPaolo AiroMarco ConfalonieriGianluca MoronciniLorenzo Dagna Marco Matucci Cerinic

Published in: RMD open (2023)

In a real-life clinical scenario, NTD, in combination with immunosuppressants, may stabilise lung function. GI side effects are frequent and NTD dose adjustment may be necessary to retain the drug in patients with SSc-ILD.

Keyphrases

interstitial lung disease
systemic sclerosis
lung function
cystic fibrosis
chronic obstructive pulmonary disease
air pollution
idiopathic pulmonary fibrosis
rheumatoid arthritis
electronic health record
big data
emergency department
adverse drug
artificial intelligence